BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 25312094)

  • 21. [A retrospective comparative study of haplotype hematopoietic stem cell transplantation and human leukocyte antigen-matched sibling donor hematopoietic stem cell transplantation in the treatment of acute B-lymphocyte leukemia].
    Wang ZD; Sun YQ; Yan CH; Wang FR; Mo XD; Lyu M; Zhao XS; Han W; Chen H; Chen YY; Wang Y; Xu LP; Wang YZ; Liu YR; Cheng YF; Zhang XH; Liu KY; Huang XJ; Chang YJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):221-228. PubMed ID: 35405780
    [No Abstract]   [Full Text] [Related]  

  • 22. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation.
    Kato M; Hasegawa D; Koh K; Kato K; Takita J; Inagaki J; Yabe H; Goto H; Adachi S; Hayakawa A; Takeshita Y; Sawada A; Atsuta Y; Kato K
    Br J Haematol; 2015 Feb; 168(4):564-70. PubMed ID: 25302748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
    Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
    Front Immunol; 2022; 13():934442. PubMed ID: 36110859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
    Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia.
    Kako S; Kanamori H; Kobayashi N; Shigematsu A; Nannya Y; Nakamae M; Shigeno K; Suzukawa K; Takeuchi M; Tsuzuki M; Usuki K; Hatanaka K; Ogawa K; Mitani K; Nawa Y; Hatta Y; Mizuno I; Kanda Y
    Br J Haematol; 2013 Apr; 161(1):95-103. PubMed ID: 23368421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.
    Pochon C; Oger E; Michel G; Dalle JH; Salmon A; Nelken B; Bertrand Y; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rohrlich P; Paillard C; Demeocq F; Schneider P; Plantaz D; Poirée M; Eliaou JF; Semana G; Drunat S; Jonveaux P; Bordigoni P; Gandemer V
    Br J Haematol; 2015 Apr; 169(2):249-61. PubMed ID: 25522886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.
    Boztug H; Zecca M; Sykora KW; Veys P; Lankester A; Slatter M; Skinner R; Wachowiak J; Pötschger U; Glogova E; Peters C;
    Ann Hematol; 2015 Feb; 94(2):297-306. PubMed ID: 25231927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
    Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia.
    Bai L; Cheng YF; Lu AD; Suo P; Wang Y; Zuo YX; Yan CH; Wu J; Jia YP; Sun YQ; Chen YH; Chen H; Liu KY; Han W; Xu LP; Wang JB; Tang XF; Chen HR; Zhang LP; Huang XJ
    Leuk Res; 2020 Apr; 91():106333. PubMed ID: 32109757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia.
    Liu DH; Xu LP; Liu KY; Wang Y; Chen H; Han W; Zhang XH; Yan CH; Zhang YY; Wang JZ; Chen YH; Wang FR; Huang XJ
    Bone Marrow Transplant; 2013 Nov; 48(12):1519-24. PubMed ID: 23892327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission.
    Yan CH; Jiang Q; Wang J; Xu LP; Liu DH; Jiang H; Chen H; Zhang XH; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1314-21. PubMed ID: 24747334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
    Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
    Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
    Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.